Holen Sie sich die Stockscreener-App
0.85
5.11%
0.0413
Vorhandelsmarkt:
.95
0.10
+11.76%
Schlusskurs vom Vortag:
$0.8087
Offen:
$0.8199
24-Stunden-Volumen:
1.02M
Relative Volume:
1.20
Marktkapitalisierung:
$109.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-3.8636
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+15.10%
1M Leistung:
+1.46%
6M Leistung:
-4.01%
1J Leistung:
-32.54%
1-Tages-Spanne:
$0.8031
$0.8699
1-Wochen-Bereich:
$0.734
$0.8699
52-Wochen-Spanne:
$0.5526
$1.2982
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.85 | 104.46M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - Setenews
Atossa Therapeutics Announces Issuance of U.S. Patent Covering E - GuruFocus
ATOS Receives New Patent for Endoxifen Formulations - GuruFocus
Atossa Therapeutics receives US patent for endoxifen formulations - Investing.com
Atossa Therapeutics (Nasdaq: ATOS) lands U.S. patent with 100 (Z)-endoxifen claims - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock - MarketBeat
Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Atossa Therapeutics (ATOS) | ATOS Stock News - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75 - Investing.com UK
CapEx per share of Atossa Therapeutics, Inc. – BER:YAG2 - TradingView
Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $6.25 - Defense World
Contrasting Vaso (OTCMKTS:VASO) and Atossa Genetics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback By Investing.com - Investing.com South Africa
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback - Investing.com
Is Atossa Therapeutics Inc. stock undervalued vs historical averagesIPO Watch & Weekly Market Pulse Alerts - Newser
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - Finviz
Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser
Atossa completes FDA meeting on regulatory strategies - MSN
Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks
Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView
Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser
Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - Lelezard
How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - Sahm
Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma - EurekAlert!
S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus
Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-12-02 04:01:13 - Newser
Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser
Atossa Therapeutics (ATOS) Stock Analysis Report | Financials & Insights - Benzinga
Will Atossa Therapeutics Inc. stock outperform international peersJuly 2025 Levels & Fast Moving Market Watchlists - BỘ NỘI VỤ
Is Atossa Therapeutics Inc (ATOS) positioned for future growth? - Setenews
Is Atossa Therapeutics Inc. stock a buy before product launches2025 Major Catalysts & Verified Momentum Watchlists - BỘ NỘI VỤ
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire) - Aktiellt
Atossa Therapeutics, Inc. (ATOS) 5.16% in After-hours: What’s Driving the Move? - Stocks Telegraph
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer (PR Newswire) - Aktiellt
Why Atossa Therapeutics Inc. (YAG2) stock is listed among top recommendationsRecession Risk & Verified High Yield Trade Plans - newser.com
Is Atossa Therapeutics Inc a good long term investmentTop Performing Stocks & Free Extraordinary Earning Power - earlytimes.in
How buybacks impact Atossa Therapeutics Inc. stock value2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock profit from AI boomWeekly Profit Report & Fast Gaining Stock Reports - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock remain on Wall Street radarWeekly Investment Report & Verified Short-Term Trading Plans - newser.com
How Atossa Therapeutics Inc. stock valuations compare to rivalsPortfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
How rising interest rates impact Atossa Therapeutics Inc. stockMarket Performance Recap & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-11-19 18:15:24 - newser.com
Published on: 2025-11-19 15:47:35 - newser.com
Is a relief rally coming for Atossa Therapeutics Inc. holdersJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):